Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 30
- Registration Number
- NCT04776590
- Locations
- 🇨🇳
Union Hospital, Wuhan, Hubei, China
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04771715
- Locations
- 🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 662
- Registration Number
- NCT04746924
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Providence Medical Foundation St Jude Heritage Healthcare, Fullerton, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 98
- Registration Number
- NCT04734262
- Locations
- 🇨🇳
Fudan University Shanghai Cancer, Shanghai, Shanghai, China
AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 125
- Registration Number
- NCT04732494
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
🇹🇭Phramongkutklao Hospital, Bangkok, Thailand
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT04730219
- Locations
- 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04730232
- Locations
- 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT04727996
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 84
- Registration Number
- NCT04716634
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷National Cancer Center (NCC), Goyang-si, Gyeonggi-do, Korea, Republic of
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China
Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04705129
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.